Home > Insider Trading > Filing (0001123292-16-002318)

Filing Details

Accession Number:: 0001123292-16-002318
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-05-23 18:01:43
Reporting Period:: 2015-11-23

Filing Date:: 2016-05-23
Accepted Time:: 2016-05-23 18:01:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1588972	Recro Pharma Inc.	REPH	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1235402	Abraham Ludomirski	490 Lapp Road Malvern PA 19355		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-11-23	11,082	$9.00	2,362,964	No	4	S	Indirect	By SCP Vitalife Partners II LP
Common Stock	Disposition	2015-11-23	3,702	$9.00	789,538	No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock	Disposition	2015-11-24	2,068	$9.01	2,360,896	No	4	S	Indirect	By SCP Vitalife Partners II LP
Common Stock	Disposition	2015-11-24	691	$9.01	788,847	No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock	Disposition	2015-11-25	4,648	$9.00	2,356,248	No	4	S	Indirect	By SCP Vitalife Partners II LP
Common Stock	Disposition	2015-11-25	1,553	$9.00	787,294	No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock	Disposition	2015-11-27	6,737	$9.00	2,349,511	No	4	S	Indirect	By SCP Vitalife Partners II LP
Common Stock	Disposition	2015-11-27	2,250	$9.00	785,044	No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock	Disposition	2015-11-30	450	$9.00	2,349,061	No	4	S	Indirect	By SCP Vitalife Partners II, L.P.
Common Stock	Disposition	2015-11-30	150	$9.00	784,894	No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock	Disposition	2016-05-19	3,748	$6.46	2,345,313	No	4	S	Indirect	By SCP Vitalife Partners II LP
Common Stock	Disposition	2016-05-19	1,252	$6.46	783,642	No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock	Disposition	2016-05-20	14,992	$6.45	2,330,321	No	4	S	Indirect	By SCP Vitalife Partners II LP
Common Stock	Disposition	2016-05-20	5,008	$6.45	778,634	No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By SCP Vitalife Partners II LP
No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
No	4	S	Indirect	By SCP Vitalife Partners II LP
No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
No	4	S	Indirect	By SCP Vitalife Partners II LP
No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
No	4	S	Indirect	By SCP Vitalife Partners II LP
No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
No	4	S	Indirect	By SCP Vitalife Partners II, L.P.
No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
No	4	S	Indirect	By SCP Vitalife Partners II LP
No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.
No	4	S	Indirect	By SCP Vitalife Partners II LP
No	4	S	Indirect	By SCP Vitalife Partners (Israel) II, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.05, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.07, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.59, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.58, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 5 to this Form 4.